OBJECTIVE: Accumulated evidence suggests that a variant within the CR1 gene (single nucleotide polymorphism rs6656401), known to increase risk for Alzheimer disease (AD), influences β-amyloid (Aβ) deposition in brain tissue. Given the biologic overlap between AD and cerebral amyloid angiopathy (CAA), a leading cause of intracerebral hemorrhage (ICH) in elderly individuals, we investigated whether rs6656401 increases the risk of CAA-related ICH and influences vascular Aβ deposition. METHODS: We performed a case-control genetic association study of 89 individuals with CAA-related ICH and 280 individuals with ICH unrelated to CAA and compared them with 324 ICH-free control subjects. We also investigated the effect of rs6656401 on risk of recurrent CAA-ICH in a prospective longitudinal cohort of ICH survivors. Finally, association with severity of histopathologic CAA was investigated in 544 autopsy specimens from 2 longitudinal studies of aging. RESULTS: rs6656401 was associated with CAA-ICH (odds ratio [OR] = 1.61, 95% confidence interval [CI] 1.19-2.17, p = 8.0 × 10(-4)) as well as with risk of recurrent CAA-ICH (hazard ratio = 1.35, 95% CI 1.04-1.76, p = 0.024). Genotype at rs6656401 was also associated with severity of CAA pathology at autopsy (OR = 1.34, 95% CI 1.05-1.71, p = 0.009). Adjustment for parenchymal amyloid burden did not cancel this effect, suggesting that, despite the correlation between parenchymal and vascular amyloid pathology, CR1 acts independently on both processes, thus increasing risk of both AD and CAA. CONCLUSION: The CR1 variant rs6656401 influences risk and recurrence of CAA-ICH, as well as the severity of vascular amyloid deposition.
OBJECTIVE: Accumulated evidence suggests that a variant within the CR1 gene (single nucleotide polymorphism rs6656401), known to increase risk for Alzheimer disease (AD), influences β-amyloid (Aβ) deposition in brain tissue. Given the biologic overlap between AD and cerebral amyloid angiopathy (CAA), a leading cause of intracerebral hemorrhage (ICH) in elderly individuals, we investigated whether rs6656401 increases the risk of CAA-related ICH and influences vascular Aβ deposition. METHODS: We performed a case-control genetic association study of 89 individuals with CAA-related ICH and 280 individuals with ICH unrelated to CAA and compared them with 324 ICH-free control subjects. We also investigated the effect of rs6656401 on risk of recurrent CAA-ICH in a prospective longitudinal cohort of ICH survivors. Finally, association with severity of histopathologic CAA was investigated in 544 autopsy specimens from 2 longitudinal studies of aging. RESULTS:rs6656401 was associated with CAA-ICH (odds ratio [OR] = 1.61, 95% confidence interval [CI] 1.19-2.17, p = 8.0 × 10(-4)) as well as with risk of recurrent CAA-ICH (hazard ratio = 1.35, 95% CI 1.04-1.76, p = 0.024). Genotype at rs6656401 was also associated with severity of CAA pathology at autopsy (OR = 1.34, 95% CI 1.05-1.71, p = 0.009). Adjustment for parenchymal amyloid burden did not cancel this effect, suggesting that, despite the correlation between parenchymal and vascular amyloid pathology, CR1 acts independently on both processes, thus increasing risk of both AD and CAA. CONCLUSION: The CR1 variant rs6656401 influences risk and recurrence of CAA-ICH, as well as the severity of vascular amyloid deposition.
Authors: H C O'Donnell; J Rosand; K A Knudsen; K L Furie; A Z Segal; R I Chiu; D Ikeda; S M Greenberg Journal: N Engl J Med Date: 2000-01-27 Impact factor: 91.245
Authors: Lori B Chibnik; Joshua M Shulman; Sue E Leurgans; Julie A Schneider; Robert S Wilson; Dong Tran; Cristin Aubin; Aron S Buchman; Christopher B Heward; Amanda J Myers; John A Hardy; Matthew J Huentelman; Jason J Corneveaux; Eric M Reiman; Denis A Evans; David A Bennett; Philip L De Jager Journal: Ann Neurol Date: 2011-03-09 Impact factor: 10.422
Authors: Jenny U Johansson; William D Brubaker; Harold Javitz; Andrew W Bergen; Denise Nishita; Abhishek Trigunaite; Andrés Crane; Justine Ceballos; Diego Mastroeni; Andrea J Tenner; Marwan Sabbagh; Joseph Rogers Journal: Alzheimers Dement Date: 2018-05-21 Impact factor: 21.566
Authors: David A Bennett; Julie A Schneider; Aron S Buchman; Lisa L Barnes; Patricia A Boyle; Robert S Wilson Journal: Curr Alzheimer Res Date: 2012-07 Impact factor: 3.498
Authors: Valerie Valant; Brendan T Keenan; Christopher D Anderson; Joshua M Shulman; William J Devan; Alison M Ayres; Kristin Schwab; Joshua N Goldstein; Anand Viswanathan; Steven M Greenberg; David A Bennett; Philip L De Jager; Jonathan Rosand; Alessandro Biffi Journal: Transl Stroke Res Date: 2012-04-12 Impact factor: 6.829